• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

New global research partnership to find treatment for dengue – DNDi

Dengue endemic-countries to take the lead in effort to tackle the rapidly spreading climate-sensitive disease with 390 million infections a year.

Home > Press releases

New global research partnership to find treatment for dengue – DNDi

Dengue endemic-countries to take the lead in effort to tackle the rapidly spreading climate-sensitive disease with 390 million infections a year.

Healthcare worker tending patient in hospital setting
Bangkok / Geneva — 26 Jan 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • Français
    • ไทย
    • 日本語

The non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) is partnering with dengue-endemic countries on a project which aims to find a safe, affordable and effective treatment for dengue within five years. The first research institution to join is the prestigious Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.

Dengue, a climate-sensitive neglected tropical disease, is one of the top ten threats to global public health worldwide. Despite an estimated 390 million infections each year in more than 100 countries, there is no specific treatment available.

‘There is no more time to lose in addressing the need for safe and effective dengue treatments that are affordable and accessible for all patients,’ said Dr Bernard Pécoul, Executive Director of DNDi, at an event in Bangkok. ‘To succeed it is critical that dengue-endemic countries are in the lead, and we are excited to be working with Thailand as our first partner.’

‘Finding treatment solutions is all the more critical as dengue spreads at rapid pace – in part as a result of climate change predicted to further intensify the impact of dengue in endemic areas as well as to see it spread to previously unaffected areas.’

Dengue symptoms can include fever, nausea, vomiting, aches, and muscle, joint or bone pain so excruciating that the disease is also known as ‘breakbone fever.’ If infection progresses to severe dengue, affected people may experience shock, internal bleeding and organ failure – there is also a risk of death. The disease places significant pressure on public health systems in endemic countries.

More than 70% of the disease burden is estimated to be in Asia, with rapidly growing incidence in other parts of the world – in particular the Americas which exceeded 3.1 million infections in 2019.  There has also been a significant increase in cases in parts of Africa. Thailand sees tens of thousands of dengue cases every year, with major outbreaks every 2-3 years, such as in 2019 when Thailand saw more than 131,000 cases.

‘Even in the midst of the COVID-19 pandemic, it is important we don’t lose sight of our efforts to tackle other diseases which affect millions of people around the world,’ said Dr Prasit Watanapa, Dean of the Faculty of Medicine Siriraj Hospital, Mahidol University.

‘Despite extensive research and development of treatments for dengue fever and progress on vaccines, we have not yet achieved sufficient results. The collaboration with DNDi is a critical first step toward working with international organizations to promote and develop the potential of Thailand as one of Southeast Asia’s most dependable medical research and development facilities, as well as to contribute to the control of dengue fever in Thailand permanently.’

Globally, the number of dengue incident cases increased by 85% from 1990 to 2019. Rising temperatures linked to climate change are predicted to see faster viral amplification of the disease, as well as increased survival, reproduction and biting rate of the mosquitoes which carry it. The number of people at risk of dengue is predicted to reach 60% of the world’s population by 2080 as a result of climate change, rapid urbanization and population growth.

The new partnership therefore aims to find a new therapeutic solution to help treat dengue fever, prevent progression to severe disease and help relieve pressure on overburdened health systems.

DNDi and its partners will work together on joint projects to progress preclinical investigations of potential dengue treatments, test the efficacy of several repurposed drug candidates and implement clinical trials of the most promising drug candidates. At the same time, they will coordinate efforts to help overcome knowledge gaps and expedite clinical research and regulatory approvals, including addressing unmet needs on diagnostics. The partnership will also focus on raising funds and mobilizing resources while openly sharing research knowledge.

DNDi is in the process of signing a similar agreement with the Translational Health Science and Technology Institute (THSTI) in India and is fast progressing discussions with the Institute of Medical Research (IMR) in the Ministry of Health, Malaysia and the Oswaldo Cruz Foundation, Brazil to develop therapeutics. Meanwhile, the organization will bring African countries, such as the Democratic Republic of Congo and Ghana, on board to carry out epidemiological studies to better understand the disease in these areas.

The scientific response to COVID-19 has seen major rapid scientific advances in global health but has also thrown into sharp relief the serious power imbalances in global health. The dengue partnership, building on DNDi’s experience in South-South cooperation with hepatitis C and COVID-19, aims to show how global health R&D coordination, collaboration, and financing can be re-imagined to support a more distributed, decentralized, and democratic approach to the production of knowledge and innovation as global public goods.

Since its creation in 2003, DNDi has developed and registered nine new treatments for neglected diseases such as sleeping sickness, visceral and cutaneous leishmaniasis, Chagas, and paediatric HIV. This is the first time its researchers will dedicate efforts to dengue.

Living with dengue: ‘It’s everywhere and there’s nothing we can do about it.’

To hear more about people’s experiences, we visited recovered dengue patients in the historic city of Malacca in Malaysia, living in the highest risk areas for dengue, known as ‘red zones’.

We met 31-year-old Ma Tan Jhii Lian (Jhii), who in 2020 was infected by dengue twice in just three months.

READ Jhii’s story

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 cases in Africa. Since its inception in 2003, DNDi has delivered nine new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org

The dengue programme will in particular build on DNDi’s experience with hepatitis C, which thanks to a successful collaboration with Malaysia’s Ministry of Health and other partners now sees Malaysian patients have access to the lowest treatment costs in South-East Asia. At the same time, the gross inequity in the global response to COVID-19 led DNDi to launch a series of initiatives, including one of the largest clinical trial networks for early COVID-19 treatments, led by low- and middle-income countries.

Media contact

Frédéric Ojardias (Geneva)
fojardias@dndi.org 
+41 79 431 62 16 

Photo credit: Luke Duggleby/www.lukeduggleby.com

Partnership Dengue Asia Thailand

Read, watch, share

Loading...
Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo